Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials

ConclusionIn the current analysis with evidence on the efficacy and safety of ZA and denosumab, the authors recommend the use of ZA or denosumab treatment for periprosthetic bone mineral density loss.Systematic review registration: PROSPERO registration number: CRD42022369273
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research